Apnimed, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Apnimed completed an upsized IPO on July 31, 2026, raising $220.8M gross proceeds (13.8M shares at $16/share). The FDA accepted the NDA for lead candidate AD109 (proposed name Oxnimbi) for obstructive sleep apnea with a PDUFA target action date of February 28, 2027. The company also secured a $150M senior credit facility from HealthCare Royalty Partners and monetized its Shionogi-Apnimed joint venture for $100M upfront, strengthening cash position to ~$172.8M at Q2 2026 (before IPO proceeds).
Why this rating
Company-changing de-risking: FDA acceptance of lead asset NDA, substantial cash raise ($220.8M), and reduced execution risk position Apnimed for potential launch. Relative to inferred small biotech size, this is materially significant for trajectory.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $29.00 ▲ 0.73% | at our read · unknown $28.79 | +10 min · unknown $28.79 ▲ 0.00% | +30 min · unknown $28.79 ▲ 0.00% | +1 hr · unknown $28.79 ▲ 0.00% | +4 hrs pending |
The stock had already moved -0.72% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.